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ABSTRACT
Background: Besifovir dipivoxil maleate (BSV) with L-carnitine is the first-line antiviral 
agent for chronic hepatitis B (CHB) infection. We investigated whether BSV combined with 
L-carnitine improves hepatic steatosis (HS).
Methods: Treatment-naïve patients with CHB who were initiated on antiviral therapy (AVT) 
were enrolled. The magnitude of HS was assessed using hepatic steatosis index (HSI), and HS 
improvement was defined as a ≥ 10% reduction in the HSI score from the baseline.
Results: The mean age of the study patients was 56 years with a male predominance (n = 178,  
64.7%). The mean body mass index (BMI), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and platelet count were 23.5 kg/m2, 49.6 IU/L, 49.0 IU/L, and 191.3 
× 109/L, respectively. The mean HSI and fibrosis (FIB)-4 index were 32.6 and 0.5, respectively. 
After 6 months of AVT, platelet count (mean, 191.3→167.0 × 109/L), fasting glucose (mean, 
113.1→105.9 mg/dL), AST (mean, 49.6→28.0 IU/L), ALT (mean, 49.0→33.9 IU/L), and total 
cholesterol (mean, 170.0→162.1 mg/dL) levels significantly decreased (all P < 0.05). In the 
BSV group, AST (mean, 95.2→30.2 IU/L) and ALT (mean, 81.1→31.1 IU/L) levels significantly 
reduced (all P < 0.05), whereas HSI and FIB-4 index were maintained (all P > 0.05). In 
the univariate analysis, age, BMI, diabetes, cirrhosis, fasting glucose level, and ALT were 
significantly associated with HS improvement (all P < 0.05).
Conclusion: BSV with L-carnitine did not show any improvement of HS in patients with 
CHB. Further prospective randomized controlled studies are needed to validate the potential 
beneficial effects of BSV with L-carnitine in CHB infection.
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a public health problem affecting more than 400 
million people worldwide.1 If untreated, chronic hepatitis B (CHB) is likely to progress to 
advanced liver diseases, such as liver cirrhosis, hepatic decompensation and hepatocellular 
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carcinoma (HCC), resulting in more than 600,000 deaths every year.2 Indeed, patients 
with HBV-related cirrhosis have a high risk of developing HCC, and its incidence rate is 
approximately up to 8% per year.3 Therefore, the primary therapeutic goal of CHB is to improve 
the long-term prognosis by preventing disease progression through potent viral suppression.
Accordingly, in the current international guidelines,4-6 nucleos(t)ide analogues with a high 
genetic barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), 
and tenofovir alafenamide (TAF), are recommended as the first-line antiviral therapy (AVT).1 
Especially in Korea, in addition to ETV, TDF, and TAF, besifovir dipivoxil maleate (BSV) with 
L-carnitine supplementation is also recommended as a first-line agent.4 BSV is a potent acyclic 
nucleoside phosphonate, which is converted into an active metabolite, a nucleos(t)ide analogue 
of guanosine monophosphate that inhibits HBV replication.7 Recent clinical trials have shown 
that BSV with L-carnitine supplementation effectively suppresses HBV replication,8-10 and that 
the antiviral efficacy and safety of BSV are comparable to those of TDF.11
Approximately, 14%–70% of cases, hepatic steatosis (HS) was noted among patients with 
CHB.12 Controversial interaction between HS and CHB has been reported.13 Some studies 
have shown that CHB is not a protective factor against fatty liver.14 Another Asian study has 
demonstrated that the level of hepatitis B surface antigen (HBsAg) in the liver decreased 
as the severity of HS worsened.15 In contrast, an unfavorable impact of HS in patients with 
CHB includes the facilitation of progression to advanced liver disease.16,17 Moreover, a 
recent study has shown that the presence of metabolic syndrome is closely associated with 
HS, and is an independent risk factor for cirrhosis and HCC among patients with CHB.18,19 
All these signify that assessment and management of co-existing HS in patients with CHB 
are important.
L-carnitine (L-beta-hydroxy-g-N-trimethylaminobutyric acid), used in combination with 
BSV, is an essential nutrient that promotes the migration of long-chain fatty acids and 
converts fat into mitochondrial energy. Administration of L-carnitine improves or prevents 
hepatic damage with various causes.20 Carnitine reduces intrahepatic lipid accumulation, 
increases the expression of metabolic products associated with β-oxidation, and significantly 
reduces fatty acid levels in the liver.21 Carnitine also ameliorates the inflammation caused 
by non-alcoholic fatty liver disease (NAFLD). Furthermore, carnitine and vitamin complex 
supplementation reduce the serum levels of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and total bilirubin in patients with NAFLD.22 In a clinical study, BSV 
reduced the serum L-carnitine level in 94.1% of 114 patients, and the level normalized after 
taking L-carnitine supplements.7
Thus, we investigated whether BSV combined with L-carnitine could improve HS when 
compared to ETV and TDF, and identified the independent predictors of improvement of HS 
in patients with CHB.
METHODS
Study participants
Between November 2017 and October 2018, 617 treatment-naïve patients with CHB who were 
initiated on AVT at Severance Hospital, Yonsei University College of Medicine (Seoul, Korea) 
were considered eligible for this retrospective cohort study. CHB was defined as the persistent 
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presence of serum HBV surface antigen (HBsAg) for at least 6 months. The exclusion criteria 
were as follows; 1) patients who were initiated on AVT except BSV, ETV, and TDF, 2) HCC at 
enrollment or any such previous history, 3) decompensated liver disease at enrollment or 
any such previous history, 4) liver transplanted status at enrollment or any such past medical 
history, 5) insufficient laboratory information, 6) treatment duration ≤ 6 months, 7) use of 
medication potentially associated with fatty liver, 8) history of any other malignancy.
Enrollment and follow-up
AVT was administered according to the treatment guidelines of the Korean Association for 
the Study of the Liver and the reimbursement guidelines of the National Health Insurance 
Service of Korea.4 After AVT initiation, each patient was followed up after 3–6 months and 
underwent laboratory tests and ultrasonographic evaluation.
Estimation of HS and liver fibrosis
In addition to ultrasonographic assessment, the magnitude of HS was assessed using hepatic 
steatosis index (HSI). The equation used for the calculation of HSI is as follows: HSI = 8 × 
ALT /AST + BMI + 2, if diabetes mellitus is present; + 2, if the patient is female; values ≥ 36 
suggest fatty liver.23 In this study, the HS improvement was defined as ≥ 10% reduction in HSI 
from the baseline. The HSI formula was developed based on a logistic regression model, in a 
retrospective cohort study that excluded patients with chronic liver diseases including CHB 
infection.23 However, HSI has acceptable diagnostic accuracy for both patients with CHB and 
the general population (area under the receiver operating characteristic curve, 0.65–0.79). 
These findings support the use of HSI to assess the degree of fatty liver in patients with 
CHB.24,25 Besides, the degree of hepatic fibrosis was identified using the fibrosis-4 index 
(FIB-4 index). The equation used for the calculation of FIB-4 index is as follows: FIB-4 index 
= (Age × AST) / (PLT × √ALT).26
Statistical analyses
All statistical analyses were conducted using IMB SPSS software, version 25.0 (SPSS Inc. 
Chicago, IL, USA) for Windows. The continuous variables were expressed as the mean ± 
standard deviation (SD), and the categorical variables were presented as frequencies with 
percentages. To examine the differences between the two groups, the continuous variables 
were compared using Student's t-test or Mann-Whitney U test and the categorical variables 
were compared using χ2 test or Fisher's exact test. Changes in variables between baseline 
and follow-up were analyzed by paired t-test. The variables that were statistically significant 
in the univariate analysis were added to a multiple logistic regression model to identify the 
independent predictors of HS improvement from the baseline. Statistical significance was 
considered for comparisons with a two-tailed P value of < 0.05.
A sample size of 275 (24 in the BSV group and 251 in the ETV or TDF group) achieved 93% 
power to detect a between group-difference of 0.25, at a significance level of 0.05. In the 
initial analysis, we assumed the rate of significant reduction in HSI in the control group (ETV 
or TDF) would be around 0%, so we set the proportion of reduction in HSI in the control 
group as 0.05. The proportion of reduction in HSI in BSV group was assumed to be 0.05 
under the null hypothesis and 0.30 under the alternative hypothesis.
Ethics statement
The study was approved by the Institutional Review Board (IRB) of Severance Hospital, 
Yonsei University Health System (IRB 4-2020-0034) and was performed according to the 
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ethical guidelines of the 1975 Helsinki declaration. The requirement of informed consent was 
waived due to the retrospective nature of this study.
RESULTS
Baseline characteristics
Among the 617 treatment-naïve patients with CHB who started AVT between November 
2017 and October 2018, 588 patients who started AVT consisting of BSV, ETV, or TDF were 
considered. After excluding 313 patients according to the exclusion criteria, 275 patients were 
finally selected for the statistical analysis (Fig. 1). The baseline characteristics of the study 
population are described in Table 1. The mean age was 56 years, with a male predominance 
(n = 178, 64.7%). Diabetes, hypertension, and liver cirrhosis were identified in 31 (11.3%), 57 
(20.7%), and 82 (29.8%) patients, respectively. The mean BMI, AST, ALT, and platelet count 
were 23.5 kg/m2, 49.6 IU/L, 49.0 IU/L, and 191.3 × 109/L, respectively. The mean HSI and FIB-4 
index were 32.6 and 0.5, respectively. While fatty liver was identified in 14 (5.1%) patients 
based on the ultrasonographic evaluation, it was diagnosed in 66 (23.6%) patients by HSI.
Comparison between patients with BSV and those with ETV or TDF
Of the study population, only 24 (8.7%) patients started AVT consisting of BSV with 
L-carnitine, whereas the other 251 (91.3%) started with ETV (n = 154, 56.0%) or TDF (n = 97, 
35.3%). The patients in the BSV group were significantly younger (mean, 48.6 vs. 56.7 years), 
and had lower fasting glucose level (mean, 99.4 vs. 114.4 mg/dL), higher AST level (mean, 
95.2 vs. 45.2 IU/L), higher ALT level (mean, 81.1 vs. 45.9 IU/L), and higher total cholesterol 
level (mean, 185.6 vs. 167.0 mg/dL) (all P < 0.05) than those in the ETV/TDF group (Table 1). 
The proportion of patients with fatty liver diagnosed by ultrasonography was higher in the 
BSV group than those in the ETV/TDF group (12.5% vs. 4.4%, P = 0.084). When HSI was used 
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617 treatment-naïve patients with CHB
who started antiviral therapy
between November 2017 and October 2018 
588 patients who started antiviral therapy
using BSV, ETV, or TDF
275 patients who were finally selected
for the statistical analysis
29 patients who started antiviral therapy except BSV, ETV, and TDF
HCC at enrollment or any such previous history
Decompensated liver disease at enrollment or any such previous history
Liver transplanted status at enrollment or any such past medical history
Insufficient laboratory information
Treatment duration ≤ 6 months
Use of medications potentially associated with fatty liver
History of other malignancy
Fig. 1. Recruitment and follow-up algorithm. A total of 617 treatment-naive patients with CHB who started 
antiviral therapy between November 2017 and October 2018. However, 29 patients who started antiviral therapy 
except BSV, ETV, and TDF were excluded. Moreover, 313 patients were excluded according to our exclusion 
criteria. Finally, 275 patients were finally selected for the statistical analysis. 
CHB = chronic hepatitis B, BSV = besifovir, ETV = entecavir, TDF = tenofovir, HCC = hepatocellular carcinoma.
to define HS, the proportion of patients with fatty liver was higher in the BSV group than 
those in the ETV/TDF group (n = 11 [45.8%] vs. n = 55 [21.9%]; P = 0.998) (Table 1).
When patients in the BSV group were compared to those in the ETV or TDF group, 
respectively, similar findings were observed, except similar fasting glucose level 
(Supplementary Table 1).
Changes in the laboratory variables, HSI, and FIB-4 index after 6 months of AVT
After 6 months of AVT, platelet count (mean, 191.3 → 167.0 × 109/L), fasting glucose (mean, 
113.1 → 105.9 mg/dL), AST (mean, 49.6 → 28.0 IU/L), ALT (mean, 49.0 → 33.9 IU/L), and total 
cholesterol (mean, 170.0 → 162.1 mg/dL) levels were significantly decreased (all P < 0.05) 
(Table 2). The HSI significantly decreased (mean, 32.6 → 31.4; P < 0.001), whereas the FIB-4 
index significantly increased (mean, 0.5 → 0.6; P < 0.001) after 6 months of AVT.
Among the patients in the BSV group, AST (mean, 95.2 → 30.2 IU/L), and ALT (mean, 81.1 
→ 31.1 IU/L) levels significantly decreased (all P < 0.05), whereas HSI and FIB-4 index were 
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Table 1. Baseline characteristics of the study population (n = 275)
Variables Total (n = 275) Besifovir with 
L-carnitine  
(n = 24, 8.7%)
Entecavir or tenofovir 
(n = 251, 91.3%)
P value
Demographic parameters
Age, yr 56.0 ± 12.2 48.6 ± 10.8 56.7 ± 12.1 0.002
Sex, male 178 (64.7) 15 (62.5) 163 (64.9) 0.811
Body mass index, kg/m2 23.5 ± 3.6 24.3 ± 3.3 23.5 ± 3.6 0.301
Diabetes 31 (11.3) 0 (0) 31 (12.4) 0.068
Hypertension 57 (20.7) 2 (8.3) 55 (21.9) 0.117
Cirrhosis 82 (29.8) 10 (41.7) 72 (28.7) 0.184
Fatty liver diagnosed by ultrasonography 14 (5.1) 3 (12.5) 11 (4.4) 0.084
Laboratory parameters
Platelet count, 109/L 191.3 ± 76.5 183.9 ± 60.8 192.0 ± 77.9 0.623
Fasting glucose, mg/dL 113.0 ± 37.3 99.4 ± 13.8 114.4 ± 38.6 < 0.001
Aspartate aminotransferase, IU/L 49.0 ± 58.3 81.1 ± 50.3 45.9 ± 58.2 0.005
Alanine aminotransferase, IU/L 49.6 ± 64.2 95.2 ± 73.3 45.2 ± 61.6 < 0.001
Total bilirubin, mg/dL 0.8 ± 0.4 0.8 ± 0.3 0.8 ± 0.5 0.938
Serum albumin, g/dL 4.1 ± 0.5 4.2 ± 0.3 4.1 ± 0.5 0.095
Serum creatinine, mg/dL 0.8 ± 0.3 0.8 ± 0.1 0.8 ± 0.3 0.705
Total cholesterol, mg/dL 168.7 ± 40.3 185.6 ± 31.8 167.0 ± 40.7 0.030
Hepatic steatosis index 32.6 ± 5.4 35.8 ± 7.1 32.3 ± 5.1 0.002
Fibrosis-4 index 0.5 ± 0.4 0.5 ± 0.6 0.5 ± 0.4 0.905
Variables are expressed as mean ± standard deviation or number (%).
Table 2. Changes in laboratory parameters, hepatic steatosis index, and fibrosis-4 index after 6 months of antiviral therapy
Variables Entire population Besifovir with L-carnitine Entecavir or tenofovir
Baseline At 6 months P value Baseline At 6 months P value Baseline At 6 months P value
Laboratory parameters
Platelet count, 109/L 191.3 ± 76.5 167.0 ± 67.0 < 0.001 183.9 ± 60.8 182.8 ± 67.9 0.792 192.0 ± 77.9 165.5 ± 70.1 < 0.001
Fasting glucose, mg/dL 113.1 ± 37.4 105.9 ± 27.5 0.001 99.4 ± 13.8 96.5 ± 9.5 0.279 114.4 ± 38.6 106.8 ± 28.5 0.001
Aspartate aminotransferase, IU/L 49.0 ± 58.3 33.9 ± 25.6 < 0.001 81.1 ± 50.3 31.1 ± 21.3 < 0.001 45.9 ± 58.2 34.1 ± 26.0 0.002
Alanine aminotransferase, IU/L 49.6 ± 64.2 28.0 ± 17.9 < 0.001 95.2 ± 73.3 30.2 ± 13.1 < 0.001 45.2 ± 61.6 27.8 ± 18.3 < 0.001
Total bilirubin, mg/dL 0.8 ± 0.4 0.8 ± 0.7 0.396 0.8 ± 0.3 0.8 ± 0.4 0.751 0.8 ± 0.5 0.8 ± 0.7 0.363
Serum albumin, g/dL 4.1 ± 0.5 4.1 ± 0.5 0.391 4.2 ± 0.3 4.3 ± 0.4 0.571 4.1 ± 0.5 4.1 ± 0.5 0.450
Serum creatinine, mg/dL 0.8 ± 0.3 0.8 ± 0.3 0.235 0.8 ± 0.1 0.8 ± 0.2 0.579 0.8 ± 0.3 0.8 ± 0.3 0.200
Total cholesterol, mg/dL 170.0 ± 40.0 162.1 ± 38.2 0.002 185.6 ± 31.8 192.7 ± 32.0 0.194 168.4 ± 40.5 158.8 ± 37.4 < 0.001
Hepatic steatosis index 32.6 ± 5.4 31.4 ± 4.9 < 0.001 35.8 ± 7.1 33.7 ± 5.3 0.118 32.3 ± 5.1 31.2 ± 4.8 < 0.001
Fibrosis-4 index 0.5 ± 0.4 0.6 ± 0.6 < 0.001 0.5 ± 0.6 0.4 ± 0.6 0.758 0.5 ± 0.4 0.6 ± 0.6 < 0.001
Variables are expressed as mean ± standard deviation.
maintained (all P > 0.05) (Table 2). Among patients in the ETV/ TDF group, platelet count, 
fasting glucose, AST and ALT levels, total cholesterol, HSI, and FIB-4 index were significantly 
changed (all P < 0.05) (Table 2). The respective changes in the laboratory parameters, HSI, 
and FIB-4 index according to ETV and TDF are enumerated in Supplementary Table 2. The 
changes in HSI according to the antiviral agents are depicted in Fig. 2.
Independent predictors of treatment outcomes
Univariate and subsequent multivariate analyses were performed to identify the independent 
predictors of improvement of HS (Table 3). In the univariate analysis, age, BMI, diabetes, 
cirrhosis, fasting glucose level, and ALT level were significantly associated with improvement 
of HS (all P < 0.05). In the subsequent multivariate analysis, lower BMI (odds ratio [OR], 
0.816; 95% confidence interval [CI], 0.727–0.917; P = 0.001), diabetes (OR, 3.272; 95% CI, 
1.089–9.825; P = 0.035), absence of cirrhosis (OR, 0.351; 95% CI, 0.135–0.909; P = 0.031), 
higher fasting glucose level (OR, 1.013; 95% CI, 1.002–1.025; P = 0.019), higher ALT level 
(OR, 1.040; 95% CI, 1.023–1.064; P < 0.001) were significantly associated with the higher 
probability of HS improvement after 6 months of AVT. However, BSV with L-carnitine 
supplementation as compared to ETV or TDF was not associated with the probability of HS 
improvement (P = 0.415).
When 66 (23.6%) patients with fatty liver based on HSI > 36 at baseline, who might benefit 
from HS improvement, were selected for a subgroup analysis, only higher ALT level (OR, 
1.214; 95% CI, 1.017–1.449; P = 0.032) was independently associated with the higher 
probability of HS improvement (Table 4). When 8 patients with fatty liver diagnosed by 
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A
Baseline After 6 months of treatment
Besifovir group (n = 24)
P = 0.118
B
Baseline After 6 months of treatment















Baseline After 6 months of treatment
Entecavir group (n = 154)
P < 0.001
D
Baseline After 6 months of treatment














Fig. 2. The changes in HSI scores according to the antiviral agents from the baseline to 6 months after treatment (A) besifovir, (B) entecavir + tenofovir, (C) 
entecavir, (D) tenofovir). 
P < 0.05 was considered statistically significant. 
HSI = hepatic steatosis index.
ultrasonography were further added (n = 74, 26.9% in total), only higher ALT level (OR, 1.228; 
95% CI, 1.025–1.470; P = 0.026) was independently associated with the higher probability of 
HS improvement (Supplementary Table 3).
DISCUSSION
Current Korean guidelines for the treatment of CHB recommend BSV as a first-line AVT 
agent, together with ETV, TDF, and TAF.4 However, a recent clinical study showed that BSV 
reduced the serum L-carnitine level in 94.1% of 114 patients, although the level normalized 
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Table 3. Binary logistic regression to identify predictors of improvement of hepatic steatosis (≥ 10% reduction in hepatic steatosis index from the baseline) after 
6 months of antiviral therapy
Variables Univariate Multivariate
OR P value OR 95% CI P value
Demographic parameters
Age, yr 0.988 0.026 0.997 0.963–1.031 0.852
Sex, male 1.668 0.244 - - -
Body mass index, kg/m2 0.837 0.001 0.816 0.727–0.917 0.001
Diabetes 4.376 0.001 3.272 1.089–9.825 0.035
Hypertension 1.199 0.974 - - -
Cirrhosis 0.392 0.005 0.351 0.135–0.909 0.031
Fatty liver diagnosed by ultrasonography 1.849 0.732 - - -
Laboratory parameters
Platelet count, 109/L 1.002 0.182 - - -
Fasting glucose, mg/dL 1.012 0.001 1.013 1.002–1.025 0.019
Aspartate aminotransferase, IU/L 0.983 0.086 - - -
Alanine aminotransferase, IU/L 1.020 < 0.001 1.043 1.023–1.064 < 0.001
Total bilirubin, mg/dL 0.909 0.906 - - -
Serum albumin, g/dL 1.489 0.736 - - -
Serum creatinine, mg/dL 0.434 0.249 - - -
Total cholesterol, mg/dL 0.586 0.757 - - -
Besifovir with L-carnitine (vs. entecavir or tenofovir) 0.709 0.415 - - -
OR = odds ratio, CI = confidence interval.
Table 4. Binary logistic regression to identify predictors of the improvement of hepatic steatosis after 6 months of antiviral therapy among the patients with fatty 
liver based on HSI > 36
Variables Univariate Multivariate
OR P value OR 95% CI P value
Demographic parameters
Age, yr 1.204 0.672 - - -
Sex, male 1.237 0.720 - - -
Body mass index, kg/m2 0.781 < 0.001 0.670 0.424–1.061 0.088
Diabetes 6.378 0.292 - - -
Hypertension 0.433 0.912 - - -
Cirrhosis 0.045 0.030 0.003 0.000–7.570 0.146
Fatty liver diagnosed by ultrasonography 2.856 0.810 - - -
Laboratory parameters
Platelet count, 109/L 1.006 0.228 - - -
Fasting glucose, mg/dL 1.020 0.174 - - -
Aspartate aminotransferase, IU/L 0.810 0.058 - - -
Alanine aminotransferase, IU/L 1.166 0.002 1.214 1.017–1.449 0.032
Total bilirubin, mg/dL 1.147 0.892 - - -
Serum albumin, g/dL 0.604 0.491 - - -
Serum creatinine, mg/dL 0.030 0.017 0.000 0.000–3.219 0.066
Total cholesterol, mg/dL 0.994 0.650 - - -
Besifovir with L-carnitine (vs. entecavir or tenofovir) 33.209 0.986 - - -
Improvement of hepatic steatosis was defined as a ≥ 10% reduction in the HSI score from the baseline.
HSI = hepatic steatosis index, OR = odds ratio, CI = confidence interval.
after taking L-carnitine supplements.7 Thus, carnitine supplementation was routinely 
applied to all patients taking BSV. In living cells, L-carnitine transports fatty acids from the 
cytosol into the mitochondria during the breakdown of lipids, for the generation of energy.21 
Moreover, carnitine administration prevents hepatic damage by reducing intrahepatic fat 
accumulation and inflammation.20-22 Because L-carnitine is an essential nutrient involved 
in fatty-acid metabolism that protects the liver, we hypothesized that L-carnitine plus BSV 
would affect the hepatic fat burden in patients with CHB.
During the 6 months follow-up period, univariate and subsequent multivariate analyses 
found that BSV with L-carnitine supplementation did not show a significant reduction in the 
amount of hepatic fat estimated by HSI as compared to that with ETV or TDF. In the subgroup 
of patients with fatty liver (HSI > 36) or those with fatty liver diagnosed by ultrasonography 
or HSI > 36, BSV with L-carnitine supplementation was not significantly associated with an 
improvement in HS.
Our study has several strengths. First, to the best of our knowledge, despite the negative 
results, this is the first study to investigate the potential effects of BSV and L-carnitine on 
fatty liver. To date, L-carnitine has been known to be effective for improving fatty liver.21 
However, because the primary aim of L-carnitine supplementation is to compensate for 
L-carnitine deficit caused by BSV, our clinical setting was different from those of the other 
previous studies,21 which supports the clinical implication of our current study.
Second, we investigated the effects of BSV and L-carnitine on fatty liver using the control 
group of patients treated with ETV and TDF, which were previously administered as the first 
line agents. In contrast to the BSV group, ETV and TDF group showed a decline in the platelet 
count and an increment in FIB-4 index, which is an unexpected phenomenon with AVT using 
high-potent antiviral agents. In addition, baseline AST and ALT levels, which are the key factors 
for calculating HSI and FIB-4 index, were significantly different between the BSV and ETV/
TDF groups. This might be a reason for the potential false negative results in the BSV group. 
Therefore, well-designed prospective randomized trials with a large sample size are required.
Third, we tried to find independent predictors for HS improvement. Higher BMI and 
presence of cirrhosis were independently associated with the lower probability of HS 
improvement. The exact reason for this phenomenon is not clear. Among the various 
mechanisms associated with HS development, obesity is a major associated risk 
factor.27 Thus, the result of this study can be partly explained by the fact that L-carnitine 
supplementation might not be sufficient to improve HS when the fat burden outside the liver 
is high. In addition, cirrhosis with structural and functional abnormality might be associated 
with poor response to L-carnitine and poor mobilization of hepatic fat. However, further 
validation studies are required to elucidate these assumptions. In another study, patients with 
non-alcoholic steatohepatitis (NASH) were found to be at increased risk for liver fibrosis, 
cirrhosis, and HCC.28 Patients with lower BMI and without diabetes or cirrhosis showed 
improvement in HS. Because fasting glucose or ALT levels are associated with diabetes or 
cirrhosis, an improvement in HS is found with low glucose or ALT levels.
This study had several limitations. First, the size of the BSV and ETV/TDF groups differed 
significantly (n = 24 vs. 251). This may have hampered detection of a beneficial effect, as 
indicated by the non-significantly higher mean reduction in HSI in the BSV group (35.8 to 33.7) 
versus the ETV/TDF group (32.3 to 31.2). Moreover, the follow-up treatment period (6 months) 
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may have been insufficient to fully determine the effect of L-carnitine on fatty liver. Therefore, 
larger-scale long-term clinical studies are needed to confirm the effects of BSV with L-carnitine 
on fatty liver in patients with CHB. Second, although recent studies partially support the use 
of HSI to assess the degree of fatty liver in patients with CHB,29,30 no evidence is available on 
whether HSI is appropriate for patients with CHB, especially those with elevated liver enzyme 
levels who require antiviral therapy. In addition, the clinical implications of a reduction in 
the HSI score of > 10% from the baseline are unclear. Furthermore, because only 10 patients 
underwent paired transient elastography, our results could not be reproduced with controlled 
attenuation parameters. Also, because this was a retrospective study, we were unable to analyze 
the serum L-carnitine level. Thus, unfortunately, we cannot confirm that our findings are due 
to the effect of L-carnitine. In further studies, changes in histological status should be assessed, 
or more reliable noninvasive surrogates and assessment of the serum carnitine level during BSV 
treatment should be implemented. Third, as this was a retrospective study performed in a single 
tertiary academic institute, the results might not be applicable to the general population. Indeed, 
the proportion of patients diagnosed with fatty liver was only 5.1%, lower than the prevalence 
rate of fatty liver in Korea (26%–40%).31,32 Similarly, the proportion of patients with HSI-based 
fatty liver was 23.6%, lower than the prevalence rate of HSI-based fatty liver in Korea (64.3%).33 
Finally, the frequency of a significant improvement in HSI was unexpectedly high in the control 
group (ETV or TDF treatment), which may explain the potential false-negative results in the BSV 
group. The reduction in total cholesterol level in patients on ETV or TDF (mean, 168.4 → 158.8 
mg/dL) was greater than that in those on BSV (mean, 185.6 → 192.7 mg/dL), which might explain 
the significant reduction in HSI in the ETV and TDF groups. However, further randomized 
prospective studies including large populations are needed to confirm this finding.34
In conclusion, BSV and L-carnitine did not show improvement of HS in patients with CHB 
receiving BSV combined with L-carnitine supplementation. However, further prospective 
randomized controlled trials are required to elucidate the potential beneficial effects of BSV 
with L-carnitine supplementation in patients with CHB.
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Baseline characteristics of the study population according to the antiviral agents
Click here to view
Supplementary Table 2
Changes in laboratory parameters, hepatic steatosis index, and fibrosis-4 index after 6 
months of entecavir and tenofovir treatment
Click here to view
Supplementary Table 3
Binary logistic regression to identify predictors of the improvement of hepatic steatosis 
after 6 months of antiviral therapy among the patients with fatty liver (diagnosed by 
ultrasonography or based on HSI > 36)
Click here to view
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